Chronic Hepatitis B
Conditions
Interventions
Dominant population interferon group:None
Non-dominant population interferon group:None
Sponsors
Tangdu Hospital, Fourth Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: a. Male or female, aged 18-65 years; b.Maintain HBsAg positive for more than 6 months; c. With nucleoside (acid) treatment for more than half a year; d. qHBsAg with a clear test date can be provided at least 2 times within 5 years (in the same laboratory ); e.HBsAg was not cleared before interferon therapy; f. Willing to participate and sign informed consent.
Exclusion criteria
Exclusion criteria: a. Combined with other viral hepatitis, alcoholic liver disease, or autoimmune liver disease; b. Co-infection with HIV; c. Patients with decompensated cirrhosis (defined as Child-Pugh score >=7 or ascites, hepatorenal syndrome, hepatic encephalopathy, or gastrointestinal bleeding in the past 6 weeks); d. A history of diagnosis of hepatocellular carcinoma; e.With liver transplantation; f. Allergy to Peg-IFN-a; g. Evidence of acute severe liver damage: ALT>=10 ULN; h. Pregnant or lactating patients; i. A history of serious mental illness, especially depression; j. History of severe seizures or use anticonvulsant drugs currently; k. History of serious heart disease (such as NYHA level III or IV, myocardial infarction within 6 months, ventricular tachyarrhythmia requiring continued treatment, unstable angina, or other significant cardiovascular disease); l. Antinuclear antibody (ANA)>1:100, or a clear history of autoimmune diseases (such as inflammatory bowel disease, idiopathic thrombocytopenic purpura, systemic lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis, Guillambarre, etc.); m. A history of thyroid disease that remains poorly controlled after standardized treatment, an increase in thyrotropin accompanied by an increase in thyroid peroxidase antibodies, and thyroid disease with clinical manifestations; n. History of severe retinopathy or clinically relevant eye disease (e.g. due to high blood pressure or diabetes, CMV retinitis, macular degeneration, high myopia).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAg clearance; | — |
Secondary
| Measure | Time frame |
|---|---|
| HBsAg seroconversion rate; | — |
Countries
China
Contacts
Public ContactKang Wen
Tangdu Hospital, Fourth Military Medical University
Outcome results
None listed